CTOs on the Move

Quanterix

www.quanterix.com

 
Quanterix is a company that is digitizing biomarker analysis with the goal of advancing the science of precision health. The company`s ultra-sensitive detection solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the role of biomarkers in the continuum of health to disease. Quanterix` technology is designed to enable much earlier disease detection, better prognosis and precise treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.quanterix.com
  • 900 Middlesex Turnpike
    Billerica, MA USA 01821
  • Phone: 617.301.9400

Executives

Name Title Contact Details
Joel Nichols
 Senior Vice President Digital and Information Profile

Funding

Quanterix raised $46M on 03/23/2016
Quanterix raised $49.7M on 10/25/2019
Quanterix raised $287.5M on 02/08/2021

Similar Companies

Aerpio Therapeutics

Aerpio Therapeutics is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector. Aerpio Therapeutics is a biopharmaceutical company focused on the development of novel therapeutics for vascular disorders with a concentration on diseases of the eye.

Adma Biologics

ADMA Biologics, Inc. is a late-stage biopharmaceutical company that develops, manufactures and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. The Company is engaged in the development and com...

Breonics

Breonics is a Otisville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oncocyte

Oncocyte’s mission is to provide tests to physicians and patients that provide answers at critical decision points during lung cancer diagnosis.

Notch Therapeutics

Notch is an immune cell therapy company developing a next-generation pipeline of off-the-shelf, universally compatible, genetically tailored T cell therapeutics derived from renewable stem cell sources for the treatment of high-impact diseases, with an initial focus on cancer.